Clarifying Regulatory Criteria Without Scope Expansion
Australia’s Therapeutic Goods Administration (TGA) announced amendments to the Clinical Decision Support System (CDSS) exemption, scheduled to take effect on 1 November 2026.
Addressing industry speculation regarding an abrupt narrowing of exemption criteria, the TGA explicitly confirmed that the amendments do not alter the existing regulatory scope of the CDSS exemption, nor do they introduce new regulatory hurdles. Instead, the amendments serve as clarifying interpretations to resolve ambiguities in the application of exemption criteria under the Therapeutic Goods (Medical Devices) Regulations 2002.
Three-Tier Classification Architecture for Medical Software
The clarification reinforces the three-tier framework governing clinical and health software in Australia:
- Excluded Software (Non-Device): Software specified in Schedule 1 (e.g., lifestyle tracking, general clinical data storage, administrative electronic health records) remains entirely outside TGA medical device regulation.
- Exempt CDSS (Device, but Exempt from Pre-market ARTG Inclusion): Software meeting the definition of a medical device that satisfies specific low-risk CDSS exemption criteria in Schedule 4, Part 2. It is exempt from pre-market inclusion on the Australian Register of Therapeutic Goods (ARTG), provided clinicians can independently review the underlying data and reasoning.
- Regulated SaMD (Mandatory ARTG Inclusion): Software featuring black-box risk scoring, automated therapy delivery, closed-loop interventions, or diagnostic image analysis where independent clinician verification is not feasible must obtain formal conformity assessment and ARTG registration as Class I, Class IIa, Class IIb, or higher SaMD.
Core Exemption Requirements and Ongoing Obligations
For clinical software developers and device manufacturers seeking to utilize the exemption pathway:
- Independent Clinician Review as the Decisive Boundary: The exemption strictly applies where the software provides analytical recommendations, risk prompts, or guidelines, but presents the underlying patient data, clinical logic, and medical references transparently. Clinicians must have the opportunity and time to independently verify the rationale rather than relying blindly on algorithmic output.
- Directive Decision-Making Excluded: Software that directly drives therapy (e.g., automated infusion control) or dictates urgent clinical interventions does not qualify for exemption.
- Mandatory Notification Within 30 Working Days: Exemption from ARTG inclusion does not equate to deregulation. Sponsors must submit an official Clinical Decision Support Software Exemption Notification Form to the TGA within 30 working days of commencing commercial or clinical supply.
- Ongoing Compliance with Essential Principles: Exempt software must continuously meet all TGA Essential Principles for safety, performance, software lifecycle validation, and cybersecurity, alongside active adverse event vigilance.
Immediate Review Steps for Sponsors and Developers
Manufacturers and health software sponsors should review their software portfolio:
- Audit Explainability in User Interfaces: Confirm that clinical decision support interfaces provide clear data traceability, allowing clinicians to click through and inspect the raw physiological parameters and medical guidelines behind each alert.
- Audit Commercial Supply Notification Status: Ensure all CDSS tools currently deployed in Australian healthcare institutions have completed the mandatory 30-day TGA exemption notification.
- Formalize SaMD Pathways for Directive Algorithms: Where algorithms operate as uninterpretable automated scorers or direct treatment drivers, initiate standard conformity assessment pathways for ARTG listing.
Sources
- Primary official sourceAmendments to the clinical decision support software exemption (opens in a new tab)Therapeutic Goods Administration